BELITE BIO Business Summary

Belite Bio, Inc. (BLTE) is a clinical-stage biopharmaceutical company primarily focused on the development of novel therapeutics for untreatable retinal degenerative eye diseases and metabolic disorders. The company currently generates no product revenue, operating instead through a capital-intensive R&D model funded by strategic equity financing, including a significant $350 million public offering in late 2025 and a $275 million private placement (PIPE). Its primary business segments are centered on its lead candidate, Tinlarebant (LBS-008), an oral therapy targeting Stargardt Disease (STGD1) and Geographic Atrophy (GA), and LBS-009, which targets liver diseases such as NASH and type 2 diabetes. Direct competitors include Apellis Pharmaceuticals, Astellas Pharma (Iveric Bio), and Alkeus Pharmaceuticals; Belite Bio distinguishes itself by offering an oral, non-invasive alternative to the injectable treatments currently dominating the geographic atrophy market, positioning it as a potential first-in-class oral disease-modifying therapy for STGD1. The company was founded by Dr. Yu-Hsin (Tom) Lin, who serves as Chairman and CEO, bringing a pedigree that includes an MBA from Columbia and a PhD in Medicine from the University of Sydney, alongside his experience as the founder of Lin BioScience. The executive suite is further bolstered by Chief Medical Officer Dr. Hendrik Scholl, a world-renowned retinal expert and former director at Johns Hopkins’ Wilmer Eye Institute, and Chief Scientific Officer Dr. Nathan Mata, a neurobiology specialist with extensive clinical development experience. Belite Bio is backed by a high-profile roster of institutional investors, including RA Capital Management, Darwin Global Management, and RTW Investments. The board features seasoned independent directors such as Dr. John Longo and Dr. Gary Biddle, providing robust governance as the company approaches its planned New Drug Application (NDA) submission for Tinlarebant in the first half of 2026.